Posted in M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes April 16, 2026 Pharmaceutical Technology Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity. M&A / DealsOncologyRead full story